当前位置: X-MOL 学术In Vivo › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Prognostic and Clinical Implications of WNK Lysine Deficient Protein Kinase 1 Expression in Patients With Hepatocellular Carcinoma
In Vivo ( IF 2.3 ) Pub Date : 2020-01-01 , DOI: 10.21873/invivo.12081
YI-JUNG HO, JUNGSHAN CHANG, KUN-TU YEH, ZHIYUAN GONG, YUEH-MIN LIN, JENG-WEI LU

Background/Aim: Hepatocellular carcinoma (HCC) is a particularly malignant form of cancer prevalent throughout the world; however, there is a pressing need for HCC biomarkers to facilitate prognosis and risk assessment. Patients and Methods: This paper reports on the potential prognostic value of WNK lysine deficient protein kinase 1 (WNK1) in cases of HCC. We analyzed the expression of WNK1 at the mRNA level using omics data from the UALCAN database. We then verified our findings through the immunohistochemical (IHC) staining of various human cancer tissue as well as 59 HCC samples paired with corresponding normal tissues. The prognostic value of mRNA or protein expression by WNK1 was evaluated using the Kaplan-Meier method. Results: Initial screening results revealed significantly higher WNK1 expression levels in HCC tissue compared to normal tissue. Verification using the paired HCC samples confirmed that the expression of WNK1 was indeed significantly higher in HCC tissue samples than in adjacent normal tissues. High WNK1 expression levels were significantly correlated with clinicopathological variables, including gender and histologic grade. Kaplan-Meier survival analysis revealed that high WNK1 expression levels were associated with poor HCC prognosis. Finally, univariate and multivariate analysis identified WNK1 as a prognostic factor for TNM stage in cases of HCC. Conclusion: In summary, WNK1 is overexpressed at the mRNA and protein levels, and correlated with poor prognosis. Thus, WNK1 expression could potentially be used as a biomarker in HCC prognosis.

中文翻译:

WNK赖氨酸缺乏蛋白激酶1在肝细胞癌患者中表达的预后和临床意义

背景/目的:肝细胞癌(HCC)是一种特别恶性的癌症,在世界范围内普遍存在。然而,迫切需要 HCC 生物标志物来促进预后和风险评估。患者和方法:本文报道了 WNK 赖氨酸缺陷蛋白激酶 1 (WNK1) 在 HCC 病例中的潜在预后价值。我们使用来自 UALCAN 数据库的组学数据分析了 WNK1 在 mRNA 水平上的表达。然后,我们通过对各种人类癌症组织以及 59 个与相应正常组织配对的 HCC 样本进行免疫组织化学 (IHC) 染色来验证我们的发现。使用 Kaplan-Meier 方法评估 WNK1 的 mRNA 或蛋白质表达的预后价值。结果:初步筛选结果显示,与正常组织相比,HCC 组织中的 WNK1 表达水平显着升高。使用配对 HCC 样本的验证证实,WNK1 在 HCC 组织样本中的表达确实显着高于在相邻正常组织中的表达。高 WNK1 表达水平与临床病理学变量(包括性别和组织学分级)显着相关。Kaplan-Meier 生存分析显示,高 WNK1 表达水平与 HCC 预后不良有关。最后,单变量和多变量分析确定 WNK1 是 HCC 病例 TNM 分期的预后因素。结论:综上所述,WNK1在mRNA和蛋白水平过表达,与预后不良相关。因此,WNK1 表达可能被用作 HCC 预后的生物标志物。使用配对 HCC 样本的验证证实,WNK1 在 HCC 组织样本中的表达确实显着高于在相邻正常组织中的表达。高 WNK1 表达水平与临床病理学变量(包括性别和组织学分级)显着相关。Kaplan-Meier 生存分析显示,高 WNK1 表达水平与 HCC 预后不良有关。最后,单变量和多变量分析确定 WNK1 是 HCC 病例 TNM 分期的预后因素。结论:综上所述,WNK1在mRNA和蛋白水平过表达,与预后不良相关。因此,WNK1 表达可能被用作 HCC 预后的生物标志物。使用配对 HCC 样本的验证证实,WNK1 在 HCC 组织样本中的表达确实显着高于在相邻正常组织中的表达。高 WNK1 表达水平与临床病理学变量(包括性别和组织学分级)显着相关。Kaplan-Meier 生存分析显示,高 WNK1 表达水平与 HCC 预后不良有关。最后,单变量和多变量分析确定 WNK1 是 HCC 病例 TNM 分期的预后因素。结论:综上所述,WNK1在mRNA和蛋白水平过表达,与预后不良相关。因此,WNK1 表达可能被用作 HCC 预后的生物标志物。
更新日期:2020-01-01
down
wechat
bug